1. |
Kovacević R, Majkić-Singh N, Ignjatović S, et al. Troponin T levels in detection of perioperative myocardial infarction after coronary artery bypass surgery. Clin Lab, 2004, 50(7-8):437-445.
|
2. |
Noora J, Ricci C, Hastings D, et al. Determination of troponin I release after CABG surgery. J Card Surg, 2005, 20(2):129-135.
|
3. |
Ioannidis JP, Karvouni E, Katritis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous intervention. J Am Coll Cardiol, 2003, 42(8):1406-1411.
|
4. |
Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-MB elevation after coronary intervention:identification of an early risk period:importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation, 2002, 106(10):1205-1210.
|
5. |
Klatte K, Chaitman BR, Theroux P, et al. Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release:results from the GUARDIAN trial. J Am Coll Cardiol, 2001, 38(4):1070-1077.
|
6. |
Steuer J, Hörte LG, Lindahl B, et al. Impact of perioperative myocar-dial injury on early and long-term outcome after coronary artery bypass grafting. Eur Heart J, 2002, 23(15):1219-1227.
|
7. |
Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation, 2002, 106(17):2180-2183.
|
8. |
Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention:results from the ARMYDA(Atorvastatin for Reduction of MYocardial Damage during Angioplasty)study. Circulation, 2004, 110(6):674-678.
|
9. |
Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary intervention.Circulation, 2003, 107(13):1750-1756.
|
10. |
Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events(Naples)II trial:impact of a single high loading dose of atorvastatin on periprocedural myocardial infar-ction. J Am Coll Cardiol, 2009, 54(23):2157-2163.
|
11. |
Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study:a randomized controlled trial. JAMA, 2001, 285(13):1711-1718.
|
12. |
Yun KH, Jeong MH, Oh SK, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol, 2009, 137(3):246-251.
|
13. |
Christenson JT. Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG. Eur J Cardiothorac Surg, 1999, 15(4):394-400.
|
14. |
Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J, 2007, 28(20):2525-2538.
|
15. |
Desager JP, Horsmans Y.Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.Clin Pharmacokinet, 1996, 31(5):348-371.
|
16. |
Erkelens DW. Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia. Cardiology, 1990, 77(Suppl 4):33-38.
|
17. |
Pritzker LB. Do lipid lowering drugs reduce the risk of coronary heart disease? Crit Rev Clin Lab Sci, 1998, 35(6):603-621.
|
18. |
Charlton-Menys V, Betteridge DJ, Colhoun H, et al. Targets of statin therapy:LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study(CARDS). Clin Chem, 2009, 55(3):473-480.
|
19. |
Mizuno Y, Jacob RF, Mason RP. Inflammation and the development of atherosclerosis. J Atheroscler Thromb, 2011, 18(5):351-358.
|
20. |
Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Eng J Med, 1994, 331(7):417-424.
|
21. |
Modena MG, Bonetti L, Coppi F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol, 2002, 40(3):505-510.
|
22. |
Maack C, Kartes T, Kilter H, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation, 2003, 108(13):1567-1574.
|
23. |
Hindler K, Shaw AD, Samuels J, et al. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology, 2006, 105(6):1260-1272.
|
24. |
Huhle G, Abletshauser C, Mayer N, et al. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res, 1999, 95(5):229-234.
|
25. |
Ommen SR, Odell JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med, 1997, 336(20):1429-1434.
|
26. |
Youn YN, Park SY, Hwang Y, et al. Impact of high-dose statin pretreatment in patients with stable angina during off-pump coronary artery bypass. Korean J Thorac Cardiovasc Surg, 2011, 44(3):208-214.
|
27. |
Neher MD, Weckbach S, Flierl MA, et al. Molecular mechanisms of inflammation and tissue injury after major trauma--is complement the "bad guy"? J Biomed Sci, 2011, 18:90.
|
28. |
Boehm J, Hauner K, Grammer J, et al. Tumor necrosis factor-α-863 C/A promoter polymorphism affects the inflammatory response after cardiac surgery. Eur J Cardiothorac Surg, 2011, 40(1):e50-e54.
|
29. |
Lai WT, Lee KT, Chu CS, et al. Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans:an effect independent on cholesterol elevation. Int J Cardiol, 2005, 98(3):459-464.
|
30. |
Bruni F, Pasqui AL, Pastorelli M, et al. Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects. Int J Cardiol, 2004, 95(2-3):269-274.
|
31. |
Alber HF, Frick M, Suessenbacher A, et al. Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study. Am Heart J, 2006, 151(1):139.
|
32. |
Dereli Y, Ege E, Kurban S, et al. Pre-operative atorvastatin therapy to decrease the systemic inflammatory response after coronary artery bypass grafting. J Int Med Res, 2008, 36(6):1248-1254.
|
33. |
Krivoy N, Adler Z, Saloma R, et al. Targeting C-reactive protein levels using high-dose atorvastatin before coronary artery bypass graft surgery. Exp Clin Cardiol, 2008, 13(4):171-174.
|